Celladon Corporation (CLDN) saw a big move last session, as the company’s shares fell nearly 9% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This reverses the recent trend for CLDN, as the stock is now up nearly 33% in the past one-month time frame.
The clinical-stage biotechnology company has seen a flat track record when it comes to current year estimate revisions over the past few weeks, and the consensus for earnings hasn’t been in a trend either. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future, and especially on earnings estimates following the recent slump.
CLDN currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.
Some better-ranked stocks in the same sector include Affymetrix Inc. (AFFX), ANI Pharmaceuticals, Inc. (ANIP) and Biogen Idec Inc. (BIIB). All these stocks hold a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
CELLADON CORP (CLDN): Free Stock Analysis Report
AFFYMETRIX INC (AFFX): Free Stock Analysis Report
ANI PHARMACEUTICALS INC (ANIP): Free Stock Analysis Report
BIOGEN IDEC INC (BIIB): Free Stock Analysis Report
Zacks Investment Research